Growth kinetics and chemoprevention of aberrant crypts in the rat colon
- PMID: 1469905
- DOI: 10.1002/jcb.240501110
Growth kinetics and chemoprevention of aberrant crypts in the rat colon
Abstract
Single and multiple colonic crypts exhibiting dysplasia that are detectable in situ by staining of rat colon with methylene blue are called aberrant crypts (AC) and may serve as an intermediate marker for colon cancer. In a characterization study, we have established the kinetics of AC growth and development over a period of 20 d following injection of rats with the carcinogen azoxymethane (AOM). AC are not present at 5 d post-injection, but are a constant feature at 10 d and thereafter. Multiple AC, presumably clonal, begin to evolve at 10 d and are consistent by 20 d, forming incipient microadenomata. We have examined 20 candidate chemopreventive agents for inhibition of AC. All agents were given in AIN-76 diet, at two dose levels, with injections of AOM. AC were measured after 5 weeks of growth. Among the most active AC-inhibiting agents were BHA, DFMO, quercetin, diallyl sulfide, 18 beta-glycyrrhetinic acid, and ascorbyl palmitate. In a post-initiation study, the differentiating agent sodium butyrate was ineffective, but piroxicam was highly effective in modulating AC growth. Further, piroxicam inhibited AC development at all stages of growth from single to polycryptal clusters of AC. The AC assay shows marked sensitivity and specificity for screening agents for chemoprevention of colon cancer.
Similar articles
-
Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression.Carcinogenesis. 2000 Jun;21(6):1149-55. Carcinogenesis. 2000. PMID: 10837003
-
Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon.Int J Cancer. 1995 Feb 8;60(4):515-9. doi: 10.1002/ijc.2910600415. Int J Cancer. 1995. PMID: 7829266
-
Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat.Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):355-60. Cancer Epidemiol Biomarkers Prev. 1996. PMID: 9162301
-
Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs.Adv Exp Med Biol. 1999;470:55-63. doi: 10.1007/978-1-4615-4149-3_6. Adv Exp Med Biol. 1999. PMID: 10709674 Review.
-
Inhibition of aberrant crypt foci by chemopreventive agents.In Vivo. 1998 Mar-Apr;12(2):159-66. In Vivo. 1998. PMID: 9627797 Review.
Cited by
-
Fecal short-chain fatty acids associated with inflammation in cotton-top tamarin model for idiopathic colitis.Dig Dis Sci. 1996 Aug;41(8):1618-24. doi: 10.1007/BF02087910. Dig Dis Sci. 1996. PMID: 8769289
-
Insulin injections promote the growth of aberrant crypt foci in the colon of rats.Nutr Cancer. 1997;27(3):316-20. doi: 10.1080/01635589709514543. Nutr Cancer. 1997. PMID: 9101563 Free PMC article.
-
A ferulic acid derivative, ethyl 3-(4'-geranyloxy-3-methoxyphenyl)-2-propenoate, as a new candidate chemopreventive agent for colon carcinogenesis in the rat.Jpn J Cancer Res. 2001 Apr;92(4):404-9. doi: 10.1111/j.1349-7006.2001.tb01109.x. Jpn J Cancer Res. 2001. PMID: 11346462 Free PMC article.
-
Calcium butyrate: Anti-inflammatory effect on experimental colitis in rats and antitumor properties.Biomed Rep. 2014 Jul;2(4):559-563. doi: 10.3892/br.2014.273. Epub 2014 May 8. Biomed Rep. 2014. PMID: 24944808 Free PMC article.
-
Glycemic index, nutrient density, and promotion of aberrant crypt foci in rat colon.Nutr Cancer. 1998;32(1):29-36. doi: 10.1080/01635589809514713. Nutr Cancer. 1998. PMID: 9824854 Free PMC article.